Scientists investigated the regulatory effect and potential mechanism of hepatocyte growth factor receptor (MET, also known as HGFR) on tumor vaccinations for liver cancer in mice.
[Signal Transduction and Targeted Therapy]
6630899 WBSMITEH items 1 apa default asc 1
Huang, X., Xu, X., Wang, X., Tang, T., Li, E., Zhang, X., Xu, J., Shen, H., Guo, C., Xu, T., Ren, J., Bai, X., & Liang, T. (2020). The AKT-independent MET–V-ATPase–MTOR axis suppresses liver cancer vaccination. Signal Transduction and Targeted Therapy, 5(1), 1–10. https://doi.org/10.1038/s41392-020-0179-x Cite
Vaccine-induced antibodies exhibited a high degree of clonal diversity, recognized five conformational antigenic sites of the genotype 1 HEV p239 antigen, and cross-reacted with other genotypes.
6445212 HR78HTBG items 1 apa default asc 1
Wen, G.-P., He, L., Tang, Z.-M., Wang, S.-L., Zhang, X., Chen, Y.-Z., Lin, X., Liu, C., Chen, J.-X., Ying, D., Chen, Z.-H., Wang, Y.-B., Luo, W.-X., Huang, S.-J., Li, S.-W., Zhang, J., Zheng, Z.-Z., Zhu, J., & Xia, N.-S. (2020). Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nature Communications, 11(1), 3971. https://doi.org/10.1038/s41467-020-17737-w Cite
Researchers found that conditioned media (CM) from peripheral blood mononuclear cells (PBMCs) stimulated with dual-acting TLR7/8 and TLR2/7 agonists were more potent drivers of inhibition of hepatisis e and hepatitis s antigen secretion from hepatitis B virus-infected primary human hepatocytes than CM from PBMCs stimulated with single-acting TLR7 or TLR9 agonists.
6445212 GTTT6LSI items 1 apa default asc 1
Janovec, V., Hodek, J., Clarova, K., Hofman, T., Dostalik, P., Fronek, J., Chlupac, J., Chaperot, L., Durand, S., Baumert, T. F., Pichova, I., Lubyova, B., Hirsch, I., & Weber, J. (2020). Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Scientific Reports, 10(1), 12767. https://doi.org/10.1038/s41598-020-69614-7 Cite
Ascentage Pharma announced that the Phase Ib study of the company’s novel MDM2-p53 inhibitor candidate APG-115 as a single agent or in combinations for the treatment of Chinese patients with relapsed/refractory acute myeloid leukemia, or relapsed/progressed high/very high risk myelodysplastic syndrome has dosed its first patient in China.
Continue reading “Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China”
The authors determined the chronological distribution of hepatitis E virus (HEV) in various tissues of HEV-challenged miniature pigs and to investigate the mechanisms underlying HEV-induced cell death in the pancreas and liver.
6445212 UTERFI5R items 1 apa default asc 1
Assembly Biosciences, Inc. have announced that the US FDA has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic hepatitis B infection. 2158 is Assembly’s second-generation core inhibitor, which is being evaluated in an ongoing global Phase II trial.
[Assembly Biosciences, Inc.]
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, has announced advancements in its hepatitis B virus program evaluating EDP-514 across different patient populations.
[Enanta Pharmaceuticals, Inc.]
Scientists studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic hepatitis B virus-infection (HBV) and 29 with resolved HBV-infection
6445212 UN93VFWN items 1 apa default asc 1
Assembly Biosciences, Inc. have announced the initiation of a Phase II trial of their potent, second-generation core inhibitor, ABI-H2158, for patients with HBeAg positive chronic hepatitis B infection without cirrhosis.
[Assembly Biosciences, Inc.]
6630899 ZPU9GQNL items 1 apa default asc 1
Investigators carried out a cross-sectional study in 97 patients with advanced hepatitis C virus (HCV)-related cirrhosis. Plasma biomarkers were measured by ProcartaPlex multiplex immunoassays.
6445212 8YL3NU4P items 1 apa default asc 1
Salgüero, S., Medrano, L. M., González-García, J., Berenguer, J., Montes, M. L., Diéz, C., … Resino, S. (2020). Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis: a cross-sectional study. Scientific Reports, 10(1), 10384. https://doi.org/10.1038/s41598-020-67159-3 Cite
Investigators give an overview of T cell receptors identified from viral hepatitis research and discuss how translational lessons learned from cancer immunotherapy can be applied to the field.
6630899 3ZWDYC3P items 1 apa default asc 1